Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 12,512 shares at $0.50 ($6K) on 2022-05-03, disclosed to the SEC on 2022-05-05.
Scheduled sale ($6k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |